Delving into the Latest Updates on Ningbo Rong AN Biological Pharmaceutical Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Ningbo Rongan Biopharmaceuticals Co., Ltd., is a wholly-owned subsidiary of Aimei Vaccines Co., Ltd., and was founded in 2001. Recognized as a "High-Tech Enterprise" by the Science and Technology Commissions of Zhejiang Province and Ningbo City, Rongan has specialized in the production and commercial distribution of human rabies vaccines (using the Vero cell platform). Currently, the company's primary focus is on the manufacturing of freeze-dried human rabies vaccines.

Tags

Other Diseases

Infectious Diseases

Prophylactic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	2

Top 5 Drug Type	Count

Prophylactic vaccine	2

The Phase 3 clinical trial of freeze-dried human rabies vaccine (human diploid cells) adopted a randomized, blinded, parallel control,non-inferiority design,and administered vaccines to participants aged 10 to 60 years with different immunization schedules (5-dose schedule group, two simple 4-dose schedule groups, and 2-1-1 schedule group) to evaluate the immunogenicity and safety of the vaccine.

Start Date31 Jul 2025

Sponsor / Collaborator

Ningbo Rong AN Biological Pharmaceutical Co. Ltd.

NCT07021703

/ RecruitingPhase 1

A Open-label, Randomized Study to Evaluate the Safety and Tolerability of Freeze-dried Human Rabies Vaccine (Human Diploid Cells) Administered to Participants With Different Immunization Schedules

The Phase 1 clinical trial of the freeze-dried human rabies vaccine (human diploid cells) will be conducted on participants aged 10 to 60. This study will design a single-arm, randomized, open-access trial with different immunization schedules (5-dose schedule and 2-1-1 schedule) to evaluate the safety and tolerability of the vaccine in participants aged 10 to 60

Start Date23 May 2025

Sponsor / Collaborator

Ningbo Rong AN Biological Pharmaceutical Co. Ltd.

NCT05939648

/ Active, not recruitingPhase 2

Randomized, Blinded, Positive and Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) Booster Vaccination in People 18 Years of Age and Older Who Have Received SARS-CoV-2 Vaccine.

This trial is a phase II clinical trial of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial was randomized, blinded, placebo controlled. To evaluate the safety and immunogenicity of the study vaccine in participants aged 18 years and older who have received SARS-CoV-2 Vaccine.

Start Date09 Oct 2023

Sponsor / Collaborator

AIM Vaccine Co., Ltd.

[+1]

100 Clinical Results associated with Ningbo Rong AN Biological Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Ningbo Rong AN Biological Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Ningbo Rong AN Biological Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Ningbo Rong AN Biological Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Approved

Login to view more data